Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Neuropsychiatric complications of efavirenz in children with HIV-1 infection
Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition is unknown. Genetically determined black South Africans who are slow metabolizers of efavirenz may be at risk of toxicity. This study describes neuropsychiatric and neurocognitive mani...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Division of Neurology
2019
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867611295140806656 |
|---|---|
| access_status_str | Open Access |
| author | Hammond Charles |
| author2 | Eley Brian |
| author_browse | Eley Brian Hammond Charles |
| author_facet | Eley Brian Hammond Charles |
| author_sort | Hammond Charles |
| collection | Thesis |
| description | Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition is unknown. Genetically determined black South Africans who are slow metabolizers of efavirenz may be at risk of toxicity. This study describes neuropsychiatric and neurocognitive manifestations of South African children with suspected efavirenz neurotoxicity. Method: This retrospective study describes clinical features of 12 children with suspected efavirenz neurotoxicity (2008 – 2014). Results: Twelve children were referred (aged 3 years 4 months to 12 years, mean 7 years 8 months; 8 indigenous African (black) and 4 mixed ancestry). Six had acute neuropsychiatric manifestations after 2-8 weeks (mean 5 weeks) on efavirenz including drowsiness, seizures, sleep disturbances, behavioural changes, ataxia and slurred speech. Symptoms resolved over a few weeks in four. Two black children were phenotypically slow metabolizers with high plasma efavirenz concentrations above normal range resulting in discontinuation of efavirenz. Nine children had neurocognitive concerns potentially exacerbated by long-term efavirenz (6-72 months therapy; mean 31 months), and showed poor performance in all neurocognitive domains. Conclusion: Efavirenz causes transient neuropsychiatric adverse effects and may contribute to poor longterm neurocognitive outcomes in HIV-infected children. Genetically slow metabolizers are at risk of neurotoxicity. Prospective studies comparing efavirenz-treated and efavirenz-naïve children are needed. |
| format | Thesis |
| id | oai:open.uct.ac.za:11427/29289 |
| institution | University of Cape Town (South Africa) |
| language | eng |
| license_str | Not specified — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository |
| publishDate | 2019 |
| publishDateRange | 2019 |
| publishDateSort | 2019 |
| publisher | Division of Neurology |
| publisherStr | Division of Neurology |
| record_format | dspace |
| source_str | UCTD — University of Cape Town Open Access Repository |
| spelling | oai:open.uct.ac.za:11427/29289 Neuropsychiatric complications of efavirenz in children with HIV-1 infection Hammond Charles Eley Brian Efavirenz neuropsychiatric neurocognitive children South Africa Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition is unknown. Genetically determined black South Africans who are slow metabolizers of efavirenz may be at risk of toxicity. This study describes neuropsychiatric and neurocognitive manifestations of South African children with suspected efavirenz neurotoxicity. Method: This retrospective study describes clinical features of 12 children with suspected efavirenz neurotoxicity (2008 – 2014). Results: Twelve children were referred (aged 3 years 4 months to 12 years, mean 7 years 8 months; 8 indigenous African (black) and 4 mixed ancestry). Six had acute neuropsychiatric manifestations after 2-8 weeks (mean 5 weeks) on efavirenz including drowsiness, seizures, sleep disturbances, behavioural changes, ataxia and slurred speech. Symptoms resolved over a few weeks in four. Two black children were phenotypically slow metabolizers with high plasma efavirenz concentrations above normal range resulting in discontinuation of efavirenz. Nine children had neurocognitive concerns potentially exacerbated by long-term efavirenz (6-72 months therapy; mean 31 months), and showed poor performance in all neurocognitive domains. Conclusion: Efavirenz causes transient neuropsychiatric adverse effects and may contribute to poor longterm neurocognitive outcomes in HIV-infected children. Genetically slow metabolizers are at risk of neurotoxicity. Prospective studies comparing efavirenz-treated and efavirenz-naïve children are needed. 2019-02-05T06:53:39Z 2019-02-05T06:53:39Z 2018 2019-01-31T11:11:46Z Master Thesis Masters MPhil http://hdl.handle.net/11427/29289 eng application/pdf Division of Neurology Faculty of Health Sciences University of Cape Town |
| spellingShingle | Efavirenz neuropsychiatric neurocognitive children South Africa Hammond Charles Neuropsychiatric complications of efavirenz in children with HIV-1 infection |
| thesis_degree_str | Master's |
| title | Neuropsychiatric complications of efavirenz in children with HIV-1 infection |
| title_full | Neuropsychiatric complications of efavirenz in children with HIV-1 infection |
| title_fullStr | Neuropsychiatric complications of efavirenz in children with HIV-1 infection |
| title_full_unstemmed | Neuropsychiatric complications of efavirenz in children with HIV-1 infection |
| title_short | Neuropsychiatric complications of efavirenz in children with HIV-1 infection |
| title_sort | neuropsychiatric complications of efavirenz in children with hiv 1 infection |
| topic | Efavirenz neuropsychiatric neurocognitive children South Africa |
| url | http://hdl.handle.net/11427/29289 |
| work_keys_str_mv | AT hammondcharles neuropsychiatriccomplicationsofefavirenzinchildrenwithhiv1infection |